A bit about Serrapeptase, Nattokinase, and Lumbrokinase

Help for the Circulatory System

Serrapeptase is apparently active in the cleaning of coronary arteries from occluding layers. Serrapeptase is an enzyme produced by serratia bacteria living on silkworms. With this enzyme the worms melt a hole out of the cocoon. Unlike other enzymes in the field of biology, Serrapeptase dissolves ‘dead’ tissue like or fibrinoid layers in the arteries which chemically could be compared to silk.



A special problem in today’s civilized society is occluding processes in the carotid arteries of the neck. Serrapeptase can be used in cases of severe narrowing of the carotid arteries. Often in patients showing severe symptoms due to the narrowing, including amaurosis fugax (intermittent blindness). The therapeutic results are excellent, certainly lifesaving. It is, however, mandatory that the therapy be conducted for a very long time. The first reliable results can be expected after 6-8 months. Even after month 18, after the onset of the therapy, the patients are improving.



Serrapeptase has been found to be an extraordinary substance for safety removing fibrous blockages from coronary arteries, particularly the carotid arteries found in the neck, which supply blood brain. Serrapeptase is a natural enzyme produced by serratia bacteria living in silkworms. Once the silkworm has completed its transformation into a moth, it uses this substance to “melt” a hole in its cocoon, so that it can escape.



The astonishing fact is that, unlike other biological enzymes,
Serrapeptase affects only non-living tissue, like the silk cocoon. This is the reason the butterfly is not harmed. For our health purposes,
Serrapeptase dissolves only dead tissues such as the old fibrous layers that clog the lining of our arteries and dangerously restrict the flow of blood and oxygen to the brain. Because of this, Serrapeptase is extremely useful in keeping arterial deposits from building up again after angioplasty (a balloon technique used to clear an artery blockage) or coronary bypass surgery has been performed.



Very often, surgeons are reluctant or unable to open partially closed carotid arteries using laser surgery. They fear that resulting debris could be pushed into smaller connecting arteries and result in a stroke and possibly death. In cases of severe arterial narrowing, Serrapeptase is used with excellent, even life-saving results. Many people have shown significant improved blood flow through their previously constricted arteries, as confirmed by ultrasound examination. Unfortunately, orthodox cardiologists do not employ this important method in their practices.

Nattokinase: A Potent and Safe Thrombolytic

Nattokinase represents the most exciting new development in the prevention and treatment of cardiovascular related diseases.



There is a low-grade chronic coagulation disorder that is very broad-based throughout the United States, as evidenced by the prevalence of cardiovascular disease. Clotting is a key factor in the evolution of chronic disease. If we can reverse silent, functional clotting problems, we can offer a profound healing tool to patients. With nattokinase, we know how to stop it. Nattokinase, and other fibrinolytic enzymes, helps keep blood optimally flowing more than any other single intervention in use.



First-hand clinical reports from doctors around the country support reveal that by dissolving branched fibrin—which coagulates prior to full clot formation—Nattokinase has proven uniquely helpful in a range of disorders in which hypercoagulation is involved. This includes atherosclerosis, infertility, high blood pressure, dysmenorrhea, fibromyalgia, deep vein thrombosis, varicose veins, hemorrhoids, andischemic strokes. Also it has proved helpful in chronic infections, where the body lays down fibrin in an attempt to seal off harmful pathogens. Nattokinase can be helpful in slowing many age-associated illnesses, since high fibrin levels create local pathology and ischemia, and block nutrient and oxygen delivery in microcirculation.



The enzyme nattokinase offers a completely natural means of helping prevent and dissolve blood clots. It closely resembles plasmin, the body’s own natural clot-dissolver, and actually enhances the body’s production of plasmin.



Nattokinase cleaves fibrin (the protein that helps our body form the ‘mesh’ of a clot from a wound or trauma). It is like our natural plant kingdom source of plasmin, and is the most potent fibrinolytic enzyme of nearly 200 foods studied for their clot-dissolving abilities. It can even outperform our own body: in one remarkable in-vitro study, nattokinase, urokinase and plasmin (all capable of dissolving clots) were placed on a plate of fibrin. A clear halo showed degraded fibrin. The halo around nattokinase was over twice the size of the halo created by the other two enzymes, which our body manufactures. It also more potent than garlic, bromelain or ginseng.



Nattokinase is a multi-dimensional supplement, useful in each of the following conditions:

• Arterial wall thrombi formation with atherosclerosis

• Atherosclerosis

• Coronary artery disease (CAD)—heart attack prevention

• Pulmonary embolism

• Atrial chamber thrombi present in chronic atrial fibrillation

• Thrombi in the eyes—known as vena Centralia retinae acresia

• Diabetes, which often leads to excess platelet aggregation

• Hypertension—a natto-rich diet or nattokinase supplements have been shown to lower blood pressure. The microscopic trauma to a vessel wall under high pressure increases platelet aggregation and the need for blood thinning in the long term management of the prevention of CAD and strokes in the presence of hypertension.

• Peripheral vascular disease—arterial atherosclerosis or venous thrombosis. Nattokinase almost always improves spider veins and varicose veins. Hemorrhoids are improved as well.

• Senile dementia in which there is poor circulation and blood supply or cerebral thrombi formation

• Ischemic stroke—prevention

• Chronic migraine—where platelet aggregation releases vasoactive chemicals implicated in migraines

• Fibromyalgia, CFS and Lyme Disease—where chronic infection produces antibodies that cross-react with endothelial cells, leading to fibrin deposition

• Dysmenorrhea—where excessive clotting causes painful cramping

• Excessively fast clotting times due to platelet aggregation



Nattokinase and Cardiac Disease: A Profound Intervention

Cardiac disease is the single leading cause of death in America. Stroke is the third leading cause. In 2005, nearly 81 million Americans suffered from high blood pressure, coronary heart disease, stroke or heart failure. But functional clotting problems do steady, silent damage long before obvious disease shows itself.



This is where the real treasure of this enzyme lies, and allows practitioners to treat cardiac disease in a way that puts patients at the forefront of preventive medicine. In fact, by breaking down fibrin, increasing blood flow and thus tissue oxygen levels, you are lowering a risk factor that is implicated in almost all chronic disease.



Atherosclerosis is a multidimensional and evolving disease process, one that begins with free radical attack on the lining of the blood vessels. In fact, atherosclerosis is much like wound healing gone awry: an area becomes inflamed and ‘wounded’, and the body brings in fibrin and platelet aggregates to repair the wound. Before pulmonary emboli, heart attacks or strokes occur, patients accumulate small micro-thrombi that are still reversible. These thrombi develop and are maintained by the gradual accumulation of excessive fibrin and by the inability of the body to break down the fibrin strands effectively. Inflamed plaques produce chemicals that slow down our innate clot-dissolving ability.



Micro-embolization is an often-overlooked component of atherosclerosis. It is fibrin that is implicated in many heart attacks, since cardiac arrest usually occurs after a plaque’s cap fractures, causing a blood clot to form over the fracture and block blood flow. Nattokinase is an ideal treatment, therefore, for heart attack patients, ischemic stroke patients, those at risk of pulmonary embolism or deep vein thrombosis—in short, any patient with a clotting problem.



Hypertension is another hallmark of atherosclerosis. Fifty million Americans suffer from hypertension. By the time hypertension manifests, the blood vessel wall is already damaged and thickened by platelet aggregation. Yet the mainstream treatment strategy is simply to lower blood pressure with medications, never considering why the hypertension is occurring in the first place or how to prevent the effects of hypertension from inducing further clotting.



Nattokinase can play a key role in treating hypertension, as well as preventing the long-term sequelae of damaged, inflamed blood vessel walls. Proof of nattokinase’s efficacy in treating high blood pressure comes from a new, randomized, controlled trial published this September in Hypertension. Scientists at Yonsei University in Korea tested 86 individuals aged 20 to 80 whose blood pressure ranged from 130 to 159 mmHg.



Each received either nattokinase at 2000 FU (fibrinolytic units) per capsule daily or a placebo. After eight weeks, those on nattokinase had significantly lower systolic and diastolic blood pressure. The researchers conclude, “These findings suggest that increased intake of nattokinase may play an important role in preventing and treating hypertension.”



Why
Nattokinase is Unique

Medical science has synthesized various compounds to help thin blood, from aspirin to warfarin, urokinase and streptokinase. Each has their role. Warfarin, for example, blocks factors in the Vitamin K clotting cascade. However, warfarin does not help a patient lower their platelet aggregation or dissolve their fibrinogen or existing clots.



A patient on warfarin is only treating one part of the clotting cascade and dietary Vitamin K toxicity has not been shown to be a significant etiology in cardiovascular disease. These patients with high fibrinogen and persistent platelet aggregation are still a walking time bomb.



Nattokinase is unique in profoundly lowering fibrinogen levels and degrading branched fibrin. It has three different mechanisms of action. It lyses fibrin directly, changes prourokinase to urokinase, and increases tissue plasminogen activator, which increases our own plasmin. At the same time, nattokinase does not actually destroy the fibrinogen molecule, as streptokinase and urokinase do. It is in a unique class of fibrinolytic agents.



We Are Suffering From A Widespread Chronic Coagulation Disorder

Nattokinase lessens excessive coagulation and thus improves circulation, increasing oxygen to tissues. That is one reason disorders such as fibromyalgia, chronic fatigue syndrome, and chronic infections such as Lyme disease and inflammatory bowel disease respond to nattokinase.



These conditions are in part triggered by pathogen-associated fibrin deposition that leads to tissue hypoxia. In chronic infection, antibodies generated in response to pathogens can cross-react with endothelial cells. The pathogens themselves induce an antibody response that is damaging to the endothelium and the capillary bed.



In a milieu of chronic inflammation and infection, fibrin and soluble fibrin are deposited by the body in response to the “wound.” This causes local ischemia and local tissue hypoxia. In fact, taking these conditions as a model, we might describe a new syndrome called chronic coagulation disorder. Most of us over the age of forty probably suffer from this to some degree. Ensuring that our blood is flowing optimally and bringing healing oxygen to every cell is an important preventive measure.



This enzyme like the guards at Buckingham Palace. It stands there stock still and the one thing it responds to is a clot, or specifically fibrin. When fibrin starts to form—immediately, nattokinase goes into action. Coumadin, on the other hand, thins out the blood by poisoning the part of the coagulation system that’s dependent on Vitamin K. Now that’s certainly one way of approaching clots. Another way is fish oil. Studies on Eskimos found they have half the risk of atherosclerosis of anyone anywhere in the world. However, what doesn’t get talked about is the fact that they have a far greater risk of stroke when a blood vessel is weak and bursts and can’t clot at all. Fish oil is basically doing a lube job on the bloodstream.



You can take two tablespoons of fish oil daily—it is not going to stop you from clotting. Then you add in nattokinase to dissolve fibrin. This will offer an effective and safe treatment for coagulation disorders.



So, for anyone who has just had a heart attack and is trying to prevent a recurrence, or just had an ischemic stroke and doesn’t want to suffer another, or for any indication where Coumadin is recommended, run as fast as you can to your nearest natural medicine doctor, someone who really knows what they’re doing, and ask them about fish oil and nattokinase. If you combine the two your odds are exceptionally high that you’ll have an effective answer to hypercoagulation without putting a yourself at risk by poisoning your Vitamin K cascade.



Nattokinase can be used for hypercoagulation states and clotting disorders. People with bone pain report that their pain vanishes when they take nattokinase. Many older women complain of bone pain, but you don’t want to put them on Coumadin and upset theirVitamin K cascade since that helps form a protein in bone. Nattokinase may do the trick. People prescribed Coumadin for atrial fibrillation, and just cannot tolerate it can use nattokinase instead Many have done fabulously with it.

New Enzyme Complex Isolated From Earthworms Is Potent Fibrinolytic

Lumbrokinase Has Anti-Platelet, Anti-Thrombotic Activity

The earthworm’s antioxidant, immune-boosting, and clot-dissolving “medicine chest” is as powerful as that of any plant and even many pharmaceuticals. Earthworms have managed to survive for millions of years despite the constant threat of extinction by microbial pathogens. If we can begin to understand their remarkable capacities, we might design similar strategies to assist our own survival.



Earthworms could have been the creatures who first demonstrated a functional dichotomy in evolution:

They evolved to be able to clean up the battlefield after having killed foreign invaders. They have cells that look very much like human natural killer cells and neutrophils when examined with cytofluorimetric analysis and microscopy. They hold healing treasures for us all.



Earthworm leukocytes can recognize human cancer cells as foreign and then kill them. Electron microscopy showed the astonishing “cinematography” of earthworm cells becoming incredibly active, throwing out “pseudopodia”, and literally tearing apart cancer cell membranes from a human cell cancer line named K562. Cancer researchers have never once been able to induce cancer in them. They could be irritated only to the point that they formed inflammatory lesions.



As Charles Darwin once wrote, “It may be doubted whether there are many other animals which have played so important a part in the history of the world.”



Leading researchers and doctors have reported on the power of lumbrokinase to:

• dissolve clots and protect against ischemic heart disease and stroke

• lower fibrinogen levels in cancer patients, which is strongly associated in scientific studies with better outcomes, less metastasis, and slower growth of tumors

• dissolve bacterial biofilms present in chronic infections in conditions like autism and Lyme disease, allowing antimicrobials to work effectively

• offer antiplatelet, anti-thrombotic and anti-apoptotic activity, remarkably regulating hypercoagulation



Earthworms: Ancient Medicine, New Science

The last few years have been a busy time for scientists exploring the medicinal treasures of earthworms. Laboratory, animal and clinical human studies have isolated enzymes and compounds that have proven to be potent fibrinolytics. In healthy human volunteers, an enzyme complex isolated from earthworms increased levels of tissue plasminogen activator (t-PA) and consequently, fibrinolytic activity—without harmful side effects. In a study in 2000 the complex was found to be beneficial for ischemic stroke, without increasing the risk of excessive bleeding as other anticoagulants can.



Using spectrofluorimetery and flow cytometry, another study found that this complex has both anti-platelet activity (by reducing calcium release), anti-thrombotic activity (by reducing intercellular adhesion molecule-1) and anti-apoptotic activity (by inhibiting a specific pathway). All these activities, the researchers conclude, were “remarkably regulated.”



Earthworms have a long history in folk medicine—as far back as the 1300’s. In ancient Burma and Laos, smallpox victims bathed in water where earthworms had been soaked. Worms were boiled in water with salt and onions and the broth given to women with postpartum weakness or difficulty nursing. In Iran dried earthworms were prescribed to help treat jaundice, and American Cherokee Indians used earthworm poultices to draw out thorns. According to the most famous ancient Chinese materia medica, earthworms could treat hemiplegia (a condition where half of the body is paralyzed), fever, and blood clots.



Worms produce unique and potent molecules. Earthworms have an immune system powerful enough to destroy other earthworm allografts, xenografts, but never autografts (an autograft is your own body’s graft; allograft is a graft of foreign material from your own species; and a xenograft is a graft from another species, such as a pig heart valve into a human).



Earthworms can kill bacteria and lyse foreign cells; their body fluid contains leukocytes that are as varied as those of many vertebrates. This is in spite of the fact that, unlike us, earthworms have no adaptive immune system, and do not form antibodies.



Earthworms happily crawl and munch their way through garbage teeming with bacteria and fungi, and not only fight off infection but alter that garbage so that their nitrogen and mineral-rich castings transform it into fertile, oxygen-rich soil. And, as practically every curious child knows, you can slice some earthworms and they will regenerate.



In the last few years, a number of the earthworm’s clot-dissolving, lytic and immune-boosting compounds have been isolated and tested in laboratory and clinical studies. In particular, research has focused on clot-dissolving molecules. Fibrinolytic enzymes have been purified and studied from several species of earthworm, including Lumbricus rubellas and Eisenia fetida, and been found to be both potent and safe. This is very good news, since according to a 2008 conference report from the American Society of Hematology, thromboembolism impacts over one million Americans a year and is responsible for more deaths annually than breast cancer, HIV and motor vehicle crashes combined!


The Key to Lumbrokinase: Active Only in the Presence of Fibrin

Lumbrokinase (LK) is a group of six, novel proteolytic enzymes derived from the earthworm Lumbricus rubellas.



In a 1992 study, a crude extract of the worm was shown to have a potent thrombolytic effect. The heat-stable, purified enzymes were first isolated in 1992 by Japanese researchers. The enzymes have potent fibrin-dissolving properties (fibrin is a protein deposited to create a mesh around a wound), decrease fibrinogen (a protein produced by the liver that is involved in the clotting cascade), lower blood viscosity and markedly reduce platelet aggregation.



Recent research suggests that LK may be effective in the treatment and prevention of ischemic heart disease, as well as myocardial infarction, thrombosis of the central vein of the retina, embolism of peripheral veins, and pulmonary embolisms.



One key, remarkable property of Lumbrokinase is that, unlike the medications streptokinase and urokinase, it is only active in the presence of fibrin. Though it dissolves fibrinogen and fibrin very specifically, it hardly hydrolyzes other important blood proteins such as plasminogen or albumin. It has the profound advantage of not causing hemorrhage due to excessive fibrinolysis. In fact, its plasminogen activator is remarkably similar to the plasminogen activator in the tissues of other species. Toxicological experiments have found no negative effects of LK on nervous, cardiovascular, respiratory and blood systems of rats, rabbits and dogs.



Long-term animal experiments show no damage to liver or kidney function, no negative influence on embryonic development, and no mutagenic effects in embryonic rats. LK has no negative effects on blood levels of glucose and lipids. And a 2001 study tested one of the six enzymes of LK to determine whether LK does indeed pass into the blood from the intestines while maintaining its biological activity. This research found that approximately 10% of the full-size enzyme could pass through the intestinal epithelium intact and into the blood. This is not surprising; research from The Hebrew University has shown that many peptides can pass intact and biologically active through the intestinal lumen into the blood.



In a laboratory experiment in 1994 from Seoul National University, lumbrokinase (the six enzymes) was extracted from the earthworm. LK was then immobilized onto a polyurethane surface to investigate its antithrombotic activity. Platelets adhered to the surface and then drastically decreased in number, suggesting that LK digested the fibrinogen and inhibited the ability of platelets to stick to the surface. Similar results were found with an experiment on a rabbit shunt in the laboratory; occlusion time was monitored and it was found that on shunts without LK, occlusion time was 32 and 42 minutes, respectively, but those with LK-immobilized polyurethane had an occlusion time of 140 minutes—as much as four times longer.



Such studies show the potential of immobilized-LK surfaces for eventual use in tissue transplantation. In one remarkable 1999 study, Lumbrokinase was tested on LK-immobilized polyurethane valves which were then fitted to total artificial hearts in three healthy lambs. In the control lamb, the valves were untreated; in the second lamb, only valves on the right were treated, and in the third lamb, only valves on the left were treated.



Implants were left in for up to three days. In the control lamb, thrombi were observed in the inlet parts of the valves. In the other two lambs, thrombi formed only on untreated control valves. Similarly, fibrinolytic activity was observed only in treated valves, and the proteolytic activity of the treated valves was three times higher than that of untreated valves.


A Potent Clot-Dissolver

Animal studies have demonstrated that LK is a potent clot-dissolver. A study in rabbits looked at LK’s ability to dissolve an embolism in the pulmonary artery. The embolism was radioactively tagged, and blood radioactivity was tested 30 minutes, one hour, two hours, three hours, and five hours after LK had been administered. Radioactivity increased markedly at three and five hours, indicating that LK had begun to dissolve the embolism and disperse it into the bloodstream. In another study rectal administration of LK reduced the size of a thrombus in the inferior vena cava in rats. And in yet another 1998 study, freeze dried Lumbricus rubellas was given to rats orally, and then plasmin activity in the blood was measured. At half a gram of LK per kilogram of weight a day, the activity doubled; at one gram, it quintupled.



These results suggest that earthworm powder alone is valuable for thrombotic conditions. Finally, grafts treated with LK and inserted into the inferior vena cava of rabbits were compared to those not treated with LK, at five hours, 1, 2 and 4 weeks after implantation of the graft. Non-treated grafts were totally occluded with thrombus only five hours after implantation. LK treated graft were clear one week later, and those treated with a special covalent bonding method were clear four weeks later. Researchers concluded LK has potential antithrombotic effects in vascular prosthesis.



Lumbrokinase may help protect against myocardial ischemia and heart attack. A 2006 study in rats from Harbin Medical University in China induced heart attack in rats by permanently clamping shut the left anterior descending coronary artery. Lumbrokinase decreased the size of the infarct in a dose-dependent manner.



Human Studies Demonstrate Potency and Efficacy

Clinical trials in humans have been equally impressive. Research has found LK safe and effective as a thrombolytic in human volunteers. A hundred and twenty milligrams of freeze-dried earthworm powder was given orally to seven healthy volunteers aged 28-52 years old, three times a day for seventeen days. Blood was withdrawn before the trial to establish a baseline, and then at days 1, 2, 3, 8 , 11 and 17. Fibrin degradation products, tissue plasminogen activator (t-PA) levels and activity were measured in the blood. The t-PA levels gradually increased through the entire experiment. Fibrinolytic activity also increased.



In an even more significant study from Shanghai Medical University in 2000, LK was used in patients who had suffered a stroke. Fifty-one stroke victims were randomly divided into a treatment group and a control group. The Chinese stroke score was used to evaluate the effect of LK. Several measures of blood viscosity were used—prothrombin time, fibrinogen content, tissue plasminogen activator (t-PA) activity, D-dimer level, and more. In the treatment group, t=PA activity and D-dimer level increased, while fibrinogen decreased significantly. Plasmingogen activator inhibitor activity and prothrombin time were unchanged.



Lumbrokinase inhibits the coagulation pathway and activates fibrinolysis by increasing t-PA activity. This suggests that LK is not only beneficial for ischemic stroke, but that doesn't increase the risk of excessive bleeding as anticoagulants can. This stroke study is backed up by a 2008 study from Harbin Medical University in China. Researchers wondered how LK might have an anti-ischemic action in the brain. Using spectrofluorimeter and flow cytometry, they found that LK has both anti-platelet activity (by reducing calcium release), anti-thrombotic activity (by reducing intercellular adhesion molecule-1) and anti-apoptotic activity (by inhibiting a specific pathway). All these activities, the researchers conclude, were “remarkably regulated by LK.”

for more immune boosting tips check http://www.rawfoodsonabudget.com
from: http://immortalhair.forumandco.com/



No comments :

Make Peace With Food

Amazon